Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1139 | 981 | 1139 | 1181 | 1433 | 2164 |
Fund Return | 13.87% | -1.86% | 13.87% | 5.72% | 7.46% | 8.02% |
Place in category | 94 | 348 | 94 | 107 | 187 | 56 |
% in Category | 4 | 16 | 4 | 6 | 11 | 4 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GS India Equity Portfolio E Acc | 4.91B | 27.41 | 10.62 | 11.44 | ||
GS Global CORE Equity Portfolio E C | 5.03B | 28.16 | 8.18 | 10.37 | ||
GS Global CORE Equity Portfolio I E | 5.03B | 29.83 | 9.58 | 11.84 | ||
Goldman Sachs Global CORE Equity Pe | 4.82B | 28.53 | 8.32 | 10.35 | ||
GS EM Equity Portfolio E Acc | 2.95B | 15.24 | -4.86 | 4.80 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 159.26M | 15.77 | 4.40 | 5.61 | ||
European Growth Fund E Acc EUR | 7.19B | 14.87 | 3.61 | 4.82 | ||
European Growth Fund Y Acc EUR | 250.21M | 16.70 | 5.28 | 6.49 | ||
European Growth Fund Y DIST EUR | 63.95M | 16.70 | 5.28 | 6.49 | ||
European Growth Fund A DIST Eue | 7.19B | 15.73 | 4.38 | 5.61 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eurx/Eurx Er Stx 50 12/2024 | DE000C6XKBY2 | 8.16 | - | - | |
Novo Nordisk B | DK0062498333 | 3.93 | 632.3 | +0.37% | |
SAP | DE0007164600 | 3.28 | 245.850 | +0.29% | |
Novartis | CH0012005267 | 2.66 | 91.09 | -0.60% | |
Life/New Ftse 100 12/2024 | GB00KKY7ZY67 | 2.42 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | BUY | Strong Buy |
Summary | Strong Buy | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review